MDROs threaten modern medicine’s progress by making common infections fatal and dramatically increasing the risk of complications for many medical procedures such as surgery, transplants and chemotherapy.
To solve this problem a global call has been issued to develop new diagnostics that detect MDROs fast enough to make time-critical clinical decisions.
More than 2 million people in the U.S. acquire a serious antibiotic-resistant bacterial infection every year and at least 23,000 people die as a result.1
Surveillance programs have been a key factor to control the spread of drug-resistant organisms in hospitals. One of the goals of these programs is to identify patients that are asymptomatic carriers of drug-resistant bacteria so that infection prevention measures (e.g. isolation, contact precautions, decolonization) may be enacted to reduce the spread of high-risk organisms in healthcare settings and decrease infection rates.
Factors that impact program success include the speed and accuracy of the diagnostic system used. Evidence for methicillin-resistant Staphylococcus aureus (MRSA) surveillance programs indicates that those that use MRSA tests with a same-shift turnaround time and high sensitivity can lead to a dramatic reduction in infection rates.
Programs incorporating universal surveillance and same-shift MRSA testing have achieved more than a 50% reduction in MRSA infection rates in community-based multi-hospital systems.2,3 Similarly, in a multinational, multicentre study conducted in Europe and Israel, a combination of MRSA screening, contact precautions, and decolonization was associated with decreasing rates of MRSA clinical cultures and MRSA infections.4